Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

被引:11
|
作者
Quan, Hongzhi [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Sixuan [1 ,2 ,3 ,4 ,5 ,6 ]
Shan, Zhongyan [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Ziyi [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Tianjun [1 ,2 ,3 ,4 ,5 ,6 ]
Hu, Yanjia [1 ,2 ,3 ,4 ,5 ,6 ]
Yao, Zhigang [1 ,2 ,3 ,4 ,6 ,7 ]
Fang, Liangjuan [8 ,9 ]
机构
[1] Cent South Univ, Hunan Key Lab Oral Hlth Res, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Hunan 3D Printing Engn Res Ctr Oral Care, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Hunan Clin Res Ctr Oral Major Dis & Oral Hlth, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Dept Oral Maxillofacial Surg, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Stomatol Hosp, Dept Oral Pathol, Changsha 410008, Hunan, Peoples R China
[8] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha 410008, Hunan, Peoples R China
[9] Cent South Univ, Key Lab Hunan Prov Neurodegenerat Disorders, Changsha 410008, Hunan, Peoples R China
基金
中国博士后科学基金;
关键词
Oral squamous cell carcinoma; Oral submucous fibrosis; Programmed death ligand-1; Programmed death 1; Prognosis; PD-L1; EXPRESSION; CANCER; MICROENVIRONMENT; BLOCKADE; GRADE;
D O I
10.1016/j.archoralbio.2020.104916
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: The aim of our study was to investigate the expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) between oral squamous cell carcinoma (OSCC) patients with and without oral submucous fibrosis (OSF), and its correlation with clinic-pathologic features and its prognostic value. Methods: PD-L1 and PD-1 expression was evaluated by immunohistochemical staining, double immunofluorescent staining and real-time PCR, and the correlation of PD-L1/PD-1 expression with clinical outcome was assessed. Results: The level of PD-L1 expression was significantly higher in OSCC with OSF than in OSCC without OSF = 0.006). Moreover, PD-L1 expression was strongly correlated with lymph node metastasis (p = 0.016), and advanced tumor stage (p = 0.030). Increased PD-L1 expression was positively correlated with the incidence of OSCC with OSF = 0.006, p = 0.008, respectively). PD-L1 expression was an independent marker of unfavorable prognosis (p = 0.035, p = 0.048, respectively). High PD-L1 expression had a significantly worse outcome in OSCC patients with OSF (p = 0.014). Double immunofluorescent staining showed that OSCC with OSF were more strongly expressed both PD-L1 and PD-1 than OSCC without OSF. Moreover, the expression of PD-L1 were upregulated in OSCC tissues than normal control (p = 0.0422), and both PD-L1 and PD-1 was significantly higher in OSCC with OSF than OSCC without OSF tissues (p = 0.0043 and, p = 0.0012, respectively). Conclusions: The present study suggested that PD-L1 may be an unfavorable indicator for prognosis. PD-L1/PD-1 signaling might play an important role in the malignant transformation of OSF, and targeting PD-L1/PD-1 signaling may be a new therapeutic strategy for OSCC, especially in OSCC patients with OSF.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition
    Kwon, Mi Jung
    Rho, Young-Soo
    Nam, Eun Sook
    Cho, Seong Jin
    Park, Hye-Rim
    Min, Soo Kee
    Seo, Jinwon
    Choe, Ji-Young
    Kim, Eun Soo
    Park, Bumjung
    Hong, Mineui
    Min, Kyueng-Whan
    HUMAN PATHOLOGY, 2018, 80 : 28 - 39
  • [42] Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics
    Wei, Ping
    Jin, Mulan
    Zhou, Xiang
    Hu, Xiumei
    Wang, Ying
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (04): : 1989 - 1998
  • [43] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [44] Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications
    Wolkow, Natalie
    Jakobiec, Frederick A.
    Afrogheh, Amir H.
    Eagle, Ralph C., Jr.
    Pai, Sara, I
    Faquin, William C.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 200 : 226 - 241
  • [45] Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
    Gu, Xiaobin
    Gao, Xian-Shu
    Xiong, Wei
    Guo, Wei
    Han, Linjun
    Bai, Yun
    Peng, Chuan
    Cui, Ming
    Xie, Mu
    ONCOTARGETS AND THERAPY, 2016, 9 : 4805 - 4813
  • [46] Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
    Zhang, Yan
    Li, Jinbao
    Lou, Jingsheng
    Zhou, Ying
    Bo, Lulong
    Zhu, Jiali
    Zhu, Keming
    Wan, Xiaojian
    Cai, Zailong
    Deng, Xiaoming
    CRITICAL CARE, 2011, 15 (01):
  • [47] The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma
    Kunkle, Christine
    Rosado, Flavia G.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (06) : 719 - 720
  • [48] Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
    Goto, Hiroyuki
    Sugita, Kazunari
    Yamamoto, Osamu
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (02) : 169 - 173
  • [49] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [50] Programmed death-ligand 1 expression in carcinoma of unknown primary
    Kim, Hye Min
    Koo, Ja Seung
    BMC CANCER, 2024, 24 (01)